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Abstract
Objective—To evaluate the clinical sig­
nificance of interleukin-6 (IL-6) measure­
m ents in relation to laboratory and 
clinical measures of disease activity and 
radiological progression in early rheuma­
toid arthritis (RA).
Methods—A prospective study was per­
formed in 51 patients with early RA during 
the first three years of the disease, with 
monthly clinical and laboratory assess­
m ents and biannual radiographs of the 
hands and feet. IL-6 was measured by 
enzyme linked immunosorbent assay 
(ELISA). Cross sectional (n=51) and 
longitudinal (n = 20) correlations between 
plasma IL-6 concentrations and values 
of C reactive protein (CRP), serum 
amyloid A protein (SAA), erythrocyte 
sedimentation rate (ESR), haemoglobin 
(Hb), platelets, and joint scores were 
calculated, and correlations made be­
tween time integrated values of IL-6, CRP 
and ESR, and radiological progression 
over three years (n “ 20),
Results—Significant correlations were 
found between IL-6 and the acute phase 
response and platelets, but variable 
results were obtained for the correlation 
between IL-6 and Hb. In contrast to a 
significant correlation between time 
integrated values of CRP or ESR and 
radiological progression, time integrated 
values of IL-6 did not correlate with 
radiological progression over three years 
follow up.
Conchision—''The course of disease activ­
ity and the radiological progression of 
joint damage are better reflected by CRP, 
SAA, and ESR values than by plasma IL-6 
concentrations, particularly in stages of 
low disease activity.
(Ann Rheum Dis 1995; 54: 674-677)
Rheumatoid arthritis (RA) is a systemic disease 
characterised by chronic inflammation of 
synovial joints. Chronic synovitis often leads to 
destruction of joint cartilage and bone, and is 
systemically accompanied by a marked acute 
phase response. Cytokines play a central role 
in both the local events and the systemic acute 
phase response. Interleukin-1 (IL-1) and
tumour necrosis factor a (TNFa) are 
considered to be the major cytokines mediating 
inflammatory joint destruction and have been 
shown to be potent inducers of IL-6 
synthesis.1 2 Though it is often present in high 
concentrations in the synovial fluid, IL-6 has 
little influence on cartilage and bone de­
struction, but appears to act rather at a 
systemic level, where its major effect is the 
induction of the hepatic synthesis of acute 
phase proteins.3 In addition, IL-6 has been 
shown to play a regulatory role in platelet 
production in vivo,4 and evidence is increasing 
that IL-6 is one of the cytokines involved in the 
aetiology of anaemia of chronic disease.5 In 
RA, measurement of the acute phase response 
by erythrocyte sedimentation rate (ESR) or C 
reactive protein (CRP) concentration is 
generally used to monitor disease activity, and 
the course of changes in CRP concentrations 
over time have been shown to be related to the 
progression of radiological joint damage in 
RA/ 1 As the inflamed synovium is thought to 
be the main source of plasma IL-6 in RA, 
theoretically, IL -6 concentrations could yield a 
more direct reflection of joint inflammation 
and destruction compared with acute phase 
reactants.
The aim of the present study was to evaluate 
the clinical significance of plasma IL-6 
measurements in relation to clinical and 
laboratory measures of disease activity and to 
radiological progression during the first years 
of RA. In addition, we analysed the relation 
between IL-6 and haemoglobin and platelet 
counts in earlv RA.
Patients and methods
PATIENTS
We analysed the data of 51 patients, selected 
from a cohort of 149 patients with RA, who 
had completed a three year follow up study: 31 
had active disease (clinical indication for 
therapeutic joint aspiration) at the time of 
investigation and 20 were selected randomly 
from those patients (132/149) who developed 
radiological joint damage within the first three 
years of the disease. All patients met the 1958 
ARA criteria for classic or definite RA and had
joint symptoms for less than one year at entry 
to the study.6 Monthly blood samples were 
available in addition to monthly clinical data, 
comprising the number of tender and swollen
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joints (52 joint score) and Ritchie articular 
index (RAI), Posteroanterior radiographs of 
the hands and feet were made every six months 
and joint damage was assessed according to 
Sharp et aV with some modifications. The 
maximum total score was 448.
Patients were treated with non-steroidal 
anti-inflammatory drugs (NSAIDs), disease 
modifying antirheumatic drugs (DMARDs), 
low dose corticosteroids, or combinations of 
these, as clinically indicated.
AS SAYS
GRP and serum amyloid A protein (SAA)
were measured by enzyme linked immuno­
sorbent assay (ELISA)H in EDTA plasma, 
haemoglobin and platelet counts were 
measured using standard procedures, and ESR 
was measured according to Westergren, 
Measurements of IL-6 were performed in 
EDTA plasma by ELISA,in using a 
combination of the anti-IL-6 monoclonal 
antibody (MAb) IL-6-16 and biotinylated 
polyclonal sheep antibody Sh-a-IL-6 (both 
kindly provided by Dr L Aarden, Amsterdam). 
Measurements were performed in serial 
dilutions (starting at 1:3) in the presence of an 
excess of normal sheep serum. As standard, we 
used recombinant human IL-6 (rhIL-6) from 
Genzyme (Boston, MA), with a range of 
detection of 3-100 pg/ml. Control experiments 
revealed that rhIL-6, spiked to normal serum 
at different concentrations, was recovered in 
this ELISA to an extent of 95-115%. Both 
intra-assay and interassay variability were 
< 10%.
S T A T IS T IC S
Correlation coefficients were calculated with 
the Spearman rank test. Mean correlations 
were assessed after Z transformation.
Results
P A T IE N T  C H A R A C T E R IS T IC S  AND T R E A T M E N T
The 51 patients studied included 38 women 
and 13 men; at entry to the study they were 
aged 16-72 years (median 52), and 50 were 
IgM rheumatoid factor positive (>10 IU/ml). 
No significant differences with regard to 
demographic and initial clinical and laboratory 
data were apparent between the 20 patients 
selected for the longitudinal studies and the 
remaining patients from the cohort who 
developed radiological damage (data not 
shown). The initial DMARD was hydroxy-
Table 1 Plasma cancel ¡[rations (concn) o f IL -6  and acute phase reactants, haemoglobin 
and platelets, and their interrelationships (Spearman correlations)
Plasma concn Correlation 
with IL-6
Correlation 
tuith C RP
IL-6 (ng/l) 51 (5~6(>2) .... *• 0*564***
CRP (mg/1) 34 (0-8-340) 0-564*** — ----■
SAA (mg/1) 36 (2-1000) 0-605*** 0-HQ1***
ESR (m m /1st li) 50 (5 “135) 0-744*** 0-654***
Hb (g/1) 124 (81-152) 0-311* -0-417**
Thrombocytes (x  10 /1) 307 (145-624) 0-565*** 0-577***
Plasma concns are median (range) of n = 5 L  IL-6 = Interleukin-6; CRP = C  reactive protein; 
SAA = serum amyloid A; ESR = erythrocyte sedimentation rate; H b =  haemoglobin.
*p < 0-05; ** p <  0-01; ***p<  0-001.
chloroquine (n = 35), intramuscular 
(n = 1 0 ), or D-penicillamine (n = 2). Four 
patients were treated with NSAIDs only.
R E L A T IO N  B E T  W HEN PI .ASM A 11.-ft A N D  T H E  
O T H E R  S Y S T E M IC  VARIABLES
For the cross sectional study (n = 51), the results 
of the samples taken at the time of joint 
aspiration (n = 31) and the samples at entry 
in the follow up study (n = 20) were used. 
Table 1 shows the values of the respective 
variables and the correlations between plasma 
IL -6 or CRP and these variables.
In the longitudinal study we evaluated the 
interrelationship between the different par­
ameters during the first three years of the 
disease in 20 patients. The within individual 
correlations between plasma IL-6 concentra­
tions and values of the concurrent laboratory 
and clinical variables (36 observations per 
patient) were calculated. 'Fable 2 shows the 
means of the within individual correlation 
coefficients and 95% confidence intervals 
(95% GIX, assessed after Z transformation of 
the individual correlation coefficients. The 
95% Cl was significant (p ^  0*05) for all mean 
correlations.
M ost patients with a significant correlation 
(p < 0*05) between IL-6 and CRP also showed 
a significant correlation between IL-6 and the 
other laboratory and the clinical variables.
In the few patients without a significant 
correlation between 11.,-6 and CRP, drug 
treatment did not differ from that received by 
the other patients- There was a sigi 
within individual correlation between CRP and
SAA values in all patients (p < 0*001), and no 
differences appeared to exist between CRP and 
SAA in relation to IL-6 .
R E L A T IO N  B E T W E E N  IL-6 A N D  KAUICU.0< JICAL 
P R O G R E S S IO N
In our patients the radiological score at entry 
to the study ranged from 0 to 37 (median 3), 
and the radiological progression score during 
the three year follow up was from 0 to 203 
(median 50). As radiological progression is 
essentially a cumulative phenomenon, 
results of the monthly values of the different 
process variables were transformed into time 
integrated values (area under the curve) 
according to the trapezoidal rule. Table 3
^ 1  * ! 2 W ithin individual correlations between plasma 
IL -6  and laboratoty and clinical variables during three 
years follow up (20  patients, ?6 obsen'ations per patient)
95% Cl
NJII
C R P
ESR 
II b
ThrombouytCN 
N o  of swollen joints 
N o  of tender joints 
RAI
0-W
<V<>00
0-200
04WÌ
0*471
0-423
0-184
0*544
0*566
0-551
o*ni
0-117 
0-110 
0-150 
0-12*
to 0-641 
in 0-651 
lo 0-62*
lu 0-277 
lo 0-551 
to 0-52H 
lo 0-1 HI 
to 0-5*11
■ ■»■I hip
Values are mean and 05“/» Cl of within individual eorrcluiioiiH 
nfter 7. transformation.
IL-6 - In te r le u k in -6 ;  C R P = -C  reactive protein; SAA ~ serum 
amyloid A; ESR = erythrocyte sedimentation rate; l ib *= haem o­
globin; RAI -  Ritchie articular index.
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Table .? Correlations between radiological progression and 
rime integrated values o f IL-6, GRP and E SR  over 3 years 
follow up (n = 20)
Correlation P
IL-6 0-226 <0'40
C R P 0-477 <0*05
ESR 0*604 <0-01
IL-6 = Inierleukin-6; CRP = C  reactive protein; HSR = cry thro 
cyte sedimentation rate,
shows the between individual correlations 
between radiological progression after three 
years and the time integrated values of IL-6, 
and the time integrated values of CRP and 
ESR during 36 months. A weak, non­
significant correlation was found between time 
integrated IL-6 values and radiological 
progression, compared with a significant 
correlation between time integrated CRP and 
ESR values and radiological progression.
Discussion
In previous studies> we and others have 
demonstrated a highly significant correlation 
between the acute phase response, joint 
swelling, and radiological progression during 
the first years of RA.f) In the present study we 
have analysed the clinical value of IL-6 
measurements in the monitoring of disease 
activity and radiological progression in early 
RA, based on the supposed role of IL-6 as 
mediator between the inflammatory process in 
the joints and the systemic acute phase 
response.
In the cross sectional study in 51 patients we 
found highly significant correlations between 
IL-6 and both the acute phase proteins and 
platelets, and a significant but weaker 
correlation between IL -6 and Hb. In the 
longitudinal study in 20 patients during three 
years follow up, similar results were found with 
highly significant within individual correlations 
between IL-6 and the different variables in the 
majority of the patients, but in fewer patients 
for Hb. However, the correlation between time 
integrated IL-6 values and radiological 
progression during three years follow up was 
not significant,
The relations between plasma IL-6 and 
acute phase proteins, and haematological 
variables in RA reported in the literature have 
been contradictory.11 n Differences in sensi­
tivity of the assays and in patient selection 
may, in part, explain these discrepancies. In 
addition, most of the studies were cross 
sectional. In our longitudinal study, the within 
individual correlations between plasma IL-6 
and the other process variables varied between 
patients. The significant correlation between 
IL-6 and platelet counts in most patients is in 
agreement with the potent thrombopoietic 
activity of IL-6 in vitro,'1 and with clinical 
reports of reactive thrombocytosis in in­
flammatory diseases.14 15 We found both 
patients with (n = 9) and patients without 
(n = I I )  a significant correlation between IL-6 
and Hb. Although a decrease in Hb values after 
administration of rhIL-6 has been described,4 
anaemia of chronic disease appears to be of
multifactorial origin, IL-6 being one of these 
factors,5 and the relative role of IL-6 compared 
with other factors may differ between patients.
IL-6 appeared to correlate very well to the 
acute phase proteins and clinical variables in 
most patients. A weak within individual 
correlation between IL-6 and these variables 
was found in only a few patients. This occurred 
predominantly in patients with low disease 
activity and low levels of IL-6 and acute phase 
proteins during a substantial period of three 
years follow up. It would appear that changes 
in the lower range of disease activity are more 
accurately reflected by CRP and SAA than by 
IL-6. It is conceivable that, at the hepatic level, 
the concentrations of IL-6 required for the 
synthesis of acute phase proteins are too small 
to be detectable in the circulation, or that the 
local hepatic concentrations of IL-6 bound to 
the receptor are greater than those of free IL-6 
in the circulation. In patients with high levels 
of IL-6 and acute phase proteins, this appeared 
to be of less influence, as was supported by the 
results of the cross sectional study which 
comprised samples mainly obtained at stages of 
high disease activity. These arguments may 
also be valid for the discrepancy between the 
time integrated IL-6 values and the time 
integrated acute phase protein values in their 
relation to radiological progression, with weak 
and highly significant correlations, respec­
tively.
We conclude that, based on the higher 
correlations between CRP and ESR and 
both clinical measurements and radiological 
progression, compared with the correlations 
with IL-6, there is as yet no case for measure­
ment of IL-6 levels instead of acute phase 
proteins as indicators of disease activity and 
radiological progression in clinical practice.
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